# Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected Subjects

> **NCT00098722** · PHASE2,PHASE3 · COMPLETED · sponsor: **ViiV Healthcare** · enrollment: 474 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Maraviroc (UK-427,857)
- **DRUG:** optimized background therapy
- **DRUG:** Maraviroc (UK-427,857)
- **DRUG:** optimized background therapy
- **DRUG:** optimized background therapy

## Key facts

- **NCT ID:** NCT00098722
- **Lead sponsor:** ViiV Healthcare
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-12
- **Primary completion:** 2007-04
- **Final completion:** 2011-04
- **Target enrollment:** 474 (ACTUAL)
- **Last updated:** 2012-05-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00098722

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00098722, "Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected Subjects". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00098722. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*